Reuters
08 Jul 2026, 04:52 UTC · 3h ago
Sino Biopharmaceutical, GSK expand alliance with China rights to respiratory drugs
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Reuters
08 Jul 2026, 04:52 UTC · 3h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
1 claim · each scored for market impact
Sino Biopharmaceutical's China unit secured rights to market two GSK respiratory drugs in mainland China. — Expanding product portfolios through partnerships with global leaders like GSK typically drives revenue growth and market share for the local distributor.
+0.40Which stocks this story touches
The company secured rights to market two respiratory drugs in mainland China, expanding its product portfolio.
The company expanded its market reach in mainland China through a strategic partnership.
Continue reading
6 related stories
Search tags
[mutual] Sino Biopharmaceutical secured rights to market two respiratory drugs from GSK in mainland China.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Proactive Investors
1h ago
